Pasithea, Evotec Ink Drug Development Pact
Author: Vandana Singh | October 11, 2021 08:34am
- Pasithea Therapeutics Corp (NASDAQ:KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research partner.
- No deal terms were disclosed.
- Pasithea aims to advance small molecule therapeutics with a focus on a specific neuroinflammatory pathway implicated in the neurobiology of depression and schizophrenia," stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
- Price Action: KTTA shares closed 1.50% lower at $2.62 on Friday.
Posted In: EVOTF EVTCY KTTA